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It was estimated at approximately 25%. However, the latter TRM
value, along with a relapse rate of 35%, did not result in a
significantly superior disease free survival (DFS) in patients
beyond 40 years of age with a donor compared with those without a
donor.
(2) The commonly used conditioning regimen prior to alloge-
neic stem cell transplantation (allo-SCT) was high dose cyclo-
phosphamide and myeloablative total body irradiation (TBI;
2  6 Gy). If patients had received irradiation before, a
combination of busulfan and cyclophosphamide was used. The
preparative regimen prior to autologous SCT contained high-
dose busulfan and cyclophosphamide.
(3) Treatment-related mortality data are specifically given in
Table 4 of our paper.1 Overall, TRM was estimated at 21% ( 2%,
SD) in the donor group and 4% ( 1%) in the no-donor group. As
most recipients of an allogeneic SCT received TBI, we cannot
compare the impact of different transplant techniques.
(4) Anthracyclins used in combination with cytarabin were
daunomycin at 45 mg/m2 for 3 days in the first cycle in the
HOVON 4/4A studies and idarubicin at 12 mg/m2 for 3 days in the
first cycle in the HOVON 29 and 42 studies. In addition, patients
treated with chemotherapy as consolidation therapy were treated
with mitoxantrone at 10 mg/m2 for 5 days (combined with
etoposide; see “Treatment protocols” in Cornelissen et al.1).
The study by Wiernik et al (cited by Ailawadhi) was performed
in patients with acute lymphoblastic leukemia. That same coopera-
tive group has also performed a study in AML, comparing
30 mg/m2 and 45 mg/m2 daunomycin in remission induction. While
a higher response rate was observed, no enhanced survival could be
demonstrated nor was excessive toxicity noted following the higher
dose level of daunomycin (45 mg/m2).2
(5) Fifty-five patients in the donor group did not proceed to
allo-SCT. They were, however, analyzed within the donor group
according to the “intention to treat” principle. Reasons for with-
drawal from allo-SCT were as follows: refusal (n 12), worsened
condition (n 9), early relapse or death (n 19), good risk
cytogenetics (n 10), and unknown causes (n 5). Thus, only a
minority of these patients did not proceed to allo-SCT because of
favorable risk AML.
(6) As stated in the discussion of our manuscript, data with
respect to FLT3 and NMP1 mutations were not available for the
majority of patients. As a result, those subsets of patients could not
be studied.
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To the editor:
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of
JAK2V617F clonal dominance
A JAK2V617F mutation is harbored by most patients with polycy-
themia vera (PV) and has pathogenetic1 and diagnostic2 relevance.
We used this molecular marker to trace origin of disease in a case of
PV manifested 5 years after autologous transplantation for acute
myeloid leukemia (AML).
A 60-year-old man was diagnosed as having AML, M2 FAB
subtype with normal karyotype, in January 1999. Complete remis-
sion was obtained after induction chemotherapy with fludarabine,
cytarabine, and idarubicin, followed by consolidation with idarubi-
cin and etoposide. He was conditioned with oral busulphan and
cyclophosphamide and reinfused with 4.3 106/kg peripheral
blood (PB)–primed C34 cells in December 1999. Clinical and
hematologic follow-up, and bone marrow (BM) biopsies per-
formed yearly thereafter, were unremarkable until March 2006,
when he reported pruritus after hot showers, visual disturbance,
and paresthesia of a few months’ duration. Spleen was palpable,
white blood cell count (WBC) was 6.1 109/L; Hb, 187 g/L (18.7
g/dL); platelet count, 517 109/L; LDH, 558 U/L; serum ferritin,
10 ng/mL; and erythropoietin 7.6 U/L; endogenous erythroid
colonies were present, and karyotype was normal. BM biopsy
showed increased cellularity with panmyelosis, prominent ery-
throid, and megakaryocytic proliferation; JAK2V617F mutation
was found,3 and diagnosis of PV was established.
Archived BM or PB samples were analyzed for V617F muta-
tion with quantitative polymerase chain reaction (PCR; sensitivity,
 1%; interassay,  3%).4 Leukemic blasts at diagnosis, BM cells
at remission, and leukapheresis were all V617F negative. A 20%
V617F allele burden was first detected in BM aspirate 4 years after
transplantation and it was 25% 1 year later (May 2005); ad hoc
revision of both biopsies failed to satisfy criteria for PV.5 At
diagnosis, granulocyte V617F allele burden was 28% (Figure 1).
Although the patient’s JAK2 genotype before AML was unknown,
normal hematologic parameters 1 year before would exclude a V617F-
negative AML transformed from preexisting, unrecognized, V617F-
positive PV.6 A JAK2V617F-positive essen-tial thrombocythemia after
transplantation for AML has also been reported.7
Availability of sequential samples after AML diagnosis allowed
us to trace emergence of mutant clone and to correlate it with
disease manifestation. In this patient, the target cell for JAK2V617F
mutation was most likely a reinfused hematopoietic stem cell
(HSC) that had been exposed to chemotherapy for AML. The time
interval between transplantation and appearance of V617F allele
was 4 years; of note, this interval is similar to that in a case of PV
that developed after chemotherapy for Hodgkin disease8 and
significantly shorter than the 10 to 20 years reported in nuclear
explosion exposure.9 Stochastic calculation of the kinetics of clonal
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dominance in animals determined that if the number of neoplastic
HSCs reaches 0.5% of total HSCs, survival and expansion of the
clone are assured.10 In this particular case, expansion and domi-
nance of a putative V617F mutant cell might have been facilitated
by the relatively low total number of HSCs after transplantation,
and therefore cannot be considered to reproduce clonal evolution
kinetics under usual circumstances. On the other hand, we ob-
served that there was only a 2-year lag phase between first
detection of mutant cells and manifestation of PV phenotype.
Therefore, although we cannot generalize from a single observa-
tion, this case supports the idea that expansion of JAK2V617F
mutant clone in PV is strictly linked with appearance of disease-
associated abnormalities.
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To the editor:
Development of original donor cell leukemia after successful engraftment from
a second donor
We read with interest the recent review in Blood on donor cell
leukemia (DCL) by Flynn and Kaufman.1 We report a case of DCL
occurring in cells from a first allogeneic stem-cell donor after the
patient received a successful transplant from a second donor,
following loss of the first donor graft.
The patient, a 32-year-old man, presented with severe aplastic
anemia in 1995. No precipitating cause of aplasia was identified.
Cytogenetic analysis, Ham test, diepoxybutane breakage analysis,
telomerase reverse transcriptase, and RNA component of telomer-
ase mutation screening were normal. Treatment with antilympho-
cyte globulin (ALG) and cyclosporin-A initially failed, but subse-
quent treatment with ALG and oxymethodone led to a 3-year
period of transfusion independence. Following disease recurrence
with life-threatening cytopenias, after informed consent and ethical
approval were obtained in accordance with the Declaration of
Helsinki, he received a reduced-intensity conditioning (RIC)
peripheral blood stem-cell transplant in June 1999 using fludara-
bine and cyclophosphamide2 and in vivo T-cell depletion with
alemtuzumab. The donor was his human leukocyte antigen (HLA)–
matched mother (donor 1), who was a low-resolution DRB1,
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Figure 1. The progressive changes of hematologic parameters (hemoglobin
[Hb], white blood cell count [WBC], and platelet count [PLT]; on the left y-axis)
and of JAK2V617F allele burden (percent value; on the right y-axis) in samples
collected at different times after AML diagnosis. Clinically relevant events
(diagnosis of AML or PV, autologous hematopoietic stem-cell transplantation [HSCT],
and onset of pruritus) are marked by arrows on the top of the figure.
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